Sheree R Schwartz1, Newton Kumwenda2, Johnstone Kumwenda3, Shu Chen2, Lynne M Mofenson4, Allan W Taylor5, Mary Glenn Fowler6, Taha E Taha7. 1. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, 615 North Wolfe Street, E7139, Baltimore, MD, 21205, USA. sschwartz@jhu.edu. 2. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, 615 North Wolfe Street, E7139, Baltimore, MD, 21205, USA. 3. Department of Medicine, College of Medicine, University of Malawi, Blantyre, Malawi. 4. Eunice Kennedy Shriver National Institute of Child Health and Human Development, Rockville, MD, USA. 5. Epidemiology Branch, Division of HIV/AIDS Prevention, National Center for HIV, Viral Hepatitis, STD and TB Prevention, Centers for Disease Control and Prevention, Atlanta, GA, USA. 6. Department of Pathology, Johns Hopkins Medical School, Baltimore, MD, USA. 7. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, 615 North Wolfe Street, E7139, Baltimore, MD, 21205, USA. ttaha1@jhu.edu.
Abstract
OBJECTIVES: Highly active antiretroviral therapy (HAART) provision to eligible HIV-infected pregnant and post-partum women is critical for optimizing maternal health. We assessed the impact of maternal HAART on HIV-free survival of breastfed infants in Malawi. METHODS: The post-exposure prophylaxis of infants-Malawi trial (2004-2009) enrolled mothers/infants during labor or immediately post-partum to evaluate 14-week extended infant antiretroviral prophylaxis for preventing HIV transmission through breastfeeding. Mothers meeting national HAART guidelines were referred for therapy. Child HIV-free survival-survival without HIV infection-was compared by maternal HAART status. RESULTS: Overall, 3022 mother-infant pairs contributed 4214 infant/person-years (PY) at-risk for HIV infection or death, with 532 events (incidence 12.6/100 PY, 95 % confidence interval [CI] 11.6-13.7). During follow-up, 349 mothers were HAART initiated; 581 remained HAART naïve with CD4 cell counts <250 cells/mm(3), and 2092 were never HAART-eligible. By 3 months, 11 % of infants with HAART naïve mothers (CD4 < 250) were infected with HIV or died versus 7 % of infants of HAART-initiated mothers and 4 % of infants of HAART-ineligible mothers. Maternal HAART was associated with a 46 % reduction in infant HIV infection or death as compared to infants with HAART naïve mothers (CD4 < 250) (adjusted hazards ratio 0.54, 95 % CI 0.36-0.81). Among HIV-exposed, uninfected infants, breastfeeding, but not HAART, was significantly associated with decreased child mortality. CONCLUSIONS: HIV infection and mortality are high during the first 3 months post-partum in infants of mothers with advanced HIV, and rapid maternal HAART initiation can significantly improve HIV-related infant outcomes. Clinical Trials Registration This study is registered at http://clinicaltrials.gov/ under trial number NCT00115648.
OBJECTIVES: Highly active antiretroviral therapy (HAART) provision to eligible HIV-infected pregnant and post-partum women is critical for optimizing maternal health. We assessed the impact of maternal HAART on HIV-free survival of breastfed infants in Malawi. METHODS: The post-exposure prophylaxis of infants-Malawi trial (2004-2009) enrolled mothers/infants during labor or immediately post-partum to evaluate 14-week extended infant antiretroviral prophylaxis for preventing HIV transmission through breastfeeding. Mothers meeting national HAART guidelines were referred for therapy. ChildHIV-free survival-survival without HIV infection-was compared by maternal HAART status. RESULTS: Overall, 3022 mother-infant pairs contributed 4214 infant/person-years (PY) at-risk for HIV infection or death, with 532 events (incidence 12.6/100 PY, 95 % confidence interval [CI] 11.6-13.7). During follow-up, 349 mothers were HAART initiated; 581 remained HAART naïve with CD4 cell counts <250 cells/mm(3), and 2092 were never HAART-eligible. By 3 months, 11 % of infants with HAART naïve mothers (CD4 < 250) were infected with HIV or died versus 7 % of infants of HAART-initiated mothers and 4 % of infants of HAART-ineligible mothers. Maternal HAART was associated with a 46 % reduction in infantHIV infection or death as compared to infants with HAART naïve mothers (CD4 < 250) (adjusted hazards ratio 0.54, 95 % CI 0.36-0.81). Among HIV-exposed, uninfected infants, breastfeeding, but not HAART, was significantly associated with decreased child mortality. CONCLUSIONS:HIV infection and mortality are high during the first 3 months post-partum in infants of mothers with advanced HIV, and rapid maternal HAART initiation can significantly improve HIV-related infant outcomes. Clinical Trials Registration This study is registered at http://clinicaltrials.gov/ under trial number NCT00115648.
Entities:
Keywords:
Breastfeeding; Child survival; HIV-1; Highly active antiretroviral therapy; Prevention of mother-to-child transmission
Authors: R L Shapiro; M D Hughes; A Ogwu; D Kitch; S Lockman; C Moffat; J Makhema; S Moyo; I Thior; K McIntosh; E van Widenfelt; J Leidner; K Powis; A Asmelash; E Tumbare; S Zwerski; U Sharma; E Handelsman; K Mburu; O Jayeoba; E Moko; S Souda; E Lubega; M Akhtar; C Wester; R Tuomola; W Snowden; M Martinez-Tristani; L Mazhani; M Essex Journal: N Engl J Med Date: 2010-06-17 Impact factor: 91.245
Authors: Charles S Chasela; Michael G Hudgens; Denise J Jamieson; Dumbani Kayira; Mina C Hosseinipour; Athena P Kourtis; Francis Martinson; Gerald Tegha; Rodney J Knight; Yusuf I Ahmed; Deborah D Kamwendo; Irving F Hoffman; Sascha R Ellington; Zebrone Kacheche; Alice Soko; Jeffrey B Wiener; Susan A Fiscus; Peter Kazembe; Innocent A Mofolo; Maggie Chigwenembe; Dorothy S Sichali; Charles M van der Horst Journal: N Engl J Med Date: 2010-06-17 Impact factor: 91.245
Authors: Taha E Taha; Johnstone Kumwenda; Stephen R Cole; Donald R Hoover; George Kafulafula; Mary Glenn Fowler; Michael C Thigpen; Qing Li; Newton I Kumwenda; Lynne Mofenson Journal: J Infect Dis Date: 2009-11-15 Impact factor: 5.226
Authors: Newton I Kumwenda; Donald R Hoover; Lynne M Mofenson; Michael C Thigpen; George Kafulafula; Qing Li; Linda Mipando; Kondwani Nkanaunena; Tsedal Mebrahtu; Marc Bulterys; Mary Glenn Fowler; Taha E Taha Journal: N Engl J Med Date: 2008-06-04 Impact factor: 91.245
Authors: Jonathan Mermin; Willy Were; John Paul Ekwaru; David Moore; Robert Downing; Prosper Behumbiize; John R Lule; Alex Coutinho; Jordan Tappero; Rebecca Bunnell Journal: Lancet Date: 2008-03-01 Impact factor: 79.321
Authors: Edmore Marinda; Jean H Humphrey; Peter J Iliff; Kuda Mutasa; Kusum J Nathoo; Ellen G Piwoz; Lawrence H Moulton; Peter Salama; Brian J Ward Journal: Pediatr Infect Dis J Date: 2007-06 Impact factor: 2.129
Authors: Helen M Nabwera; Joyline Jepkosgei; Kelly W Muraya; Amin S Hassan; Catherine S Molyneux; Rehema Ali; Andrew M Prentice; James A Berkley; Martha K Mwangome Journal: Int Breastfeed J Date: 2017-07-12 Impact factor: 3.461
Authors: C Horwood; L Haskins; I M Engebretsen; S Phakathi; C Connolly; A Coutsoudis; L Spies Journal: BMC Public Health Date: 2018-06-19 Impact factor: 3.295
Authors: Zachary Kwena; Liza Kimbo; Lynae A Darbes; Abigail M Hatcher; Anna Helova; George Owino; Harsha Thirumurthy; Elizabeth A Bukusi; Thomas Braun; Meredith Kilgore; Maria Pisu; Ashutosh Tamhane; Van T Nghiem; Kawango Agot; Torsten B Neilands; Janet M Turan Journal: Trials Date: 2021-01-06 Impact factor: 2.279